BACKGROUND: This prospective population-based study describes health-related quality of life (HRQOL) and disease-specific complaints of patients with multiple myeloma (MM) up to 10 yr post-diagnosis. METHODS: The Eindhoven Cancer Registry was used to select all patients diagnosed with MM from 1999 to 2010. Patients with MM completed the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires at baseline (n = 156; 74% response rate) and 1 yr later (n = 80). The EORTC QLQ-C30 was also completed by an age- and sex-matched normative population (n = 500). RESULTS: Patients with MM reported statistically significant and clinically relevant worse scores on all EORTC QLQ-C30 scales (all P's at least < 0.01) compared to the norm. Also, patients with MM reported a mean decrease (e.g., worsening) between baseline and 1-yr follow-up scores for: quality of life (mean, 68 vs. 55, respectively, P < 0.001; 74% of patients had a deteriorated score), fatigue (33 vs. 39, P < 0.05; 50%), nausea and vomiting (6.3 vs. 13, P < 0.05; 71%), pain (33 vs. 43, P < 0.05; 59%), and dyspnea (17 vs. 33, P < 0.001; 66%). The most bothering symptoms during the past week were tingling hands/feet (32%), back pain (28%), bone aches/pain (26%), pain in arm/shoulder (19%), and feeling drowsy (18%). Also, 37% worried about their future health, 34% thought about their disease, and 21% worried about dying. CONCLUSION: Patients with MM experience a very high symptom burden and low HRQOL. Future studies should focus on possible mechanisms that can predict low HRQOL and high symptom burden in patients with MM and should investigate optimal ways to alleviate these.
BACKGROUND: This prospective population-based study describes health-related quality of life (HRQOL) and disease-specific complaints of patients with multiple myeloma (MM) up to 10 yr post-diagnosis. METHODS: The Eindhoven Cancer Registry was used to select all patients diagnosed with MM from 1999 to 2010. Patients with MM completed the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires at baseline (n = 156; 74% response rate) and 1 yr later (n = 80). The EORTC QLQ-C30 was also completed by an age- and sex-matched normative population (n = 500). RESULTS:Patients with MM reported statistically significant and clinically relevant worse scores on all EORTC QLQ-C30 scales (all P's at least < 0.01) compared to the norm. Also, patients with MM reported a mean decrease (e.g., worsening) between baseline and 1-yr follow-up scores for: quality of life (mean, 68 vs. 55, respectively, P < 0.001; 74% of patients had a deteriorated score), fatigue (33 vs. 39, P < 0.05; 50%), nausea and vomiting (6.3 vs. 13, P < 0.05; 71%), pain (33 vs. 43, P < 0.05; 59%), and dyspnea (17 vs. 33, P < 0.001; 66%). The most bothering symptoms during the past week were tingling hands/feet (32%), back pain (28%), bone aches/pain (26%), pain in arm/shoulder (19%), and feeling drowsy (18%). Also, 37% worried about their future health, 34% thought about their disease, and 21% worried about dying. CONCLUSION:Patients with MM experience a very high symptom burden and low HRQOL. Future studies should focus on possible mechanisms that can predict low HRQOL and high symptom burden in patients with MM and should investigate optimal ways to alleviate these.
Authors: Erin E Kent; Anita Ambs; Sandra A Mitchell; Steven B Clauser; Ashley Wilder Smith; Ron D Hays Journal: Cancer Date: 2014-11-04 Impact factor: 6.860
Authors: Kevin W Song; Meletios A Dimopoulos; Katja C Weisel; Philippe Moreau; Antonio Palumbo; Andrew Belch; Stephen Schey; Pieter Sonneveld; Lars Sternas; Xin Yu; Ramesh Amatya; Mara S Monzini; Mohamed Zaki; Christian Jacques; Jesus San Miguel Journal: Haematologica Date: 2014-11-25 Impact factor: 9.941
Authors: Thomas van Gelder; Brendan Mulhern; Dounya Schoormans; Olga Husson; Richard De Abreu Lourenço Journal: Qual Life Res Date: 2020-01-14 Impact factor: 4.147
Authors: Olga Husson; Floortje Mols; Lonneke van de Poll-Franse; Jolanda de Vries; Goof Schep; Melissa S Y Thong Journal: Support Care Cancer Date: 2015-01-06 Impact factor: 3.603
Authors: Francesco Sparano; Michele Cavo; Pasquale Niscola; Tommaso Caravita; Fabio Efficace Journal: Support Care Cancer Date: 2018-03-20 Impact factor: 3.603
Authors: R Baz; H M Lin; A-M Hui; R D Harvey; K Colson; K Gallop; P Swinburn; J Laubach; D Berg; P Richardson Journal: Support Care Cancer Date: 2015-02-24 Impact factor: 3.603
Authors: Michel Delforge; Leonard Minuk; Jean-Claude Eisenmann; Bertrand Arnulf; Letizia Canepa; Alberto Fragasso; Serge Leyvraz; Christian Langer; Yousef Ezaydi; Dan T Vogl; Pilar Giraldo-Castellano; Sung-Soo Yoon; Charles Zarnitsky; Martine Escoffre-Barbe; Bernard Lemieux; Kevin Song; Nizar Jacques Bahlis; Shien Guo; Mara Silva Monzini; Annette Ervin-Haynes; Vanessa Houck; Thierry Facon Journal: Haematologica Date: 2015-03-13 Impact factor: 9.941
Authors: A J M Beijers; G Vreugdenhil; S Oerlemans; M Eurelings; M C Minnema; C M Eeltink; L V van de Poll-Franse; F Mols Journal: Support Care Cancer Date: 2015-12-03 Impact factor: 3.603